Acriflavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronaviruses

The data published by Polish and German scientists revealed the beneficial effects of acriflavine (ACF) in inhibiting coronavirus replication by blocking the SARS-CoV-2 (PLpro) enzyme. The PLpro protease is necessary for the maturation of the viral proteins and the suppression of the human immune response. In addition, scientists have proven that ACF is effective in inhibiting other beta-coronaviruses, making ACF a potentially important therapeutic agent to help fight other pandemics in the future. The studies were carried out using human respiratory epithelial cell cultures and mouse models. Work published in Cell Chemical Biology.